Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Jennifer L Sabol"'
Publikováno v:
Clinical breast cancer. 22(4)
Male breast cancer (MBC) is often diagnosed at a later stage and with a more unfavorable tumor-to-breast ratio compared to women, prompting lower rates of breast conservation (BCT). We sought to assess the practice patterns of neoadjuvant therapy (NT
Autor:
Ralph L. Corsetti, Jennifer L. Sabol, Ilana F. Gareen, Seema A. Khan, Constance D. Lehman, Bradley S. Snyder, Justin Romanoff, Shinn Huey S Chou, Habib Rahbar, Christopher Comstock, Sara H. Javid, Joseph A. Sparano, Ruth C. Carlos, Antonio C. Wolff, John R. Bumberry, Constantine Gatsonis, Linda K. Han, Lynne I. Wagner, Kathy D. Miller, Jennifer Xiao, Derrick W. Spell, Sunil Badve
Publikováno v:
Radiology
BACKGROUND: There are limited data from clinical trials describing preoperative MRI features and performance in the evaluation of mammographically detected ductal carcinoma in situ (DCIS). PURPOSE: To report qualitative MRI features of DCIS, MRI perf
Autor:
Austin D, Williams, Meghan, Buckley, Robin M, Ciocca, Jennifer L, Sabol, Sharon L, Larson, Ned Z, Carp
Publikováno v:
Breast cancer research and treatment. 192(1)
Many studies have demonstrated disparities in breast cancer (BC) incidence and mortality among Black women. We hypothesized that in Pennsylvania (PA), a large economically diverse state, BC diagnosis and mortality would be similar among races when st
Publikováno v:
Annals of surgical oncology. 28(10)
The National Accreditation Program of Breast Centers (NAPBC) certifies institutions that provide quality breast care. Whereas low socioeconomic status (SES) has a negative impact on patient outcomes, it is unknown whether an institution's patient SES
Autor:
Soudabeh Fazeli, Bradley S. Snyder, Ilana F. Gareen, Constance D. Lehman, Seema A. Khan, Justin Romanoff, Constantine A. Gatsonis, Ralph L. Corsetti, Habib Rahbar, Derrick W. Spell, Kenneth B. Blankstein, Linda K. Han, Jennifer L. Sabol, John R. Bumberry, Kathy D. Miller, Joseph A. Sparano, Christopher E. Comstock, Lynne I. Wagner, Ruth C. Carlos
Publikováno v:
JAMA Network Open. 5:e2210331
Guiding treatment decisions for women with ductal carcinoma in situ (DCIS) requires understanding patient preferences and the influence of preoperative magnetic resonance imaging (MRI) and surgeon recommendation.To identify factors associated with su
Autor:
Margaretha Wallon, Jonah D Klein, Zachary Aukers, Nolan Metz, Vibha Ahudja, Laura Mandik-Nayak, Vincenzo Ciocca, Vlasta Zemba-Palko, Robin M Ciocca, Jennifer L Sabol, Ned Z Carp
Publikováno v:
Cancer Research. 82:P4-04
Background: Breast cancers are traditionally viewed as immunologically silent. However, recent research has demonstrated that the triple-negative breast cancer (TNBC) and HER-2 positive (HER2) are capable of stimulating the immune system. In contrast
Autor:
Jennifer L Sabol, Ned Z. Carp, UM Wallon, Z Aukers, John James Kennedy, Robin M Ciocca, Jonah D. Klein
Publikováno v:
Cancer Research. 79:P4-06
Background: Breast cancer is traditionally not considered as a highly immunogenic disease. Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer with reported high genomic instability and high mutation rate, indicating the possi
Publikováno v:
Annals of Surgical Oncology. 28:601-601
Autor:
Constantine Gatsonis, John R. Bumberry, Bradley S. Snyder, Linda K. Han, Joseph A. Sparano, Seema A. Khan, Derrick W. Spell, Lynne I. Wagner, Jennifer L. Sabol, Kathy D. Miller, Habib Rahbar, Ralph L. Corsetti, Ruth C. Carlos, Justin Romanoff, Ilana F. Gareen, Soudabeh Fazeli, Kenneth Bruce Blankstein, Constance D. Lehman, Christopher Comstock
Publikováno v:
Journal of Clinical Oncology. 39:6564-6564
6564 Background: Management of ductal carcinoma in situ (DCIS) remains variable, requiring an understanding of patient preferences and concerns to enhance the treatment decision-making process. Pre-operative MRI and surgeon recommendation can further
Publikováno v:
Cancer Research. 76:P2-05
Breast cancer with HER2 gene amplification accounts for 20-25% of invasive breast cancer. HER2 activates the PI3K/Akt and MAPK pathways promoting survival and cell proliferation resulting in aggressive biological behavior and poorer prognosis for the